PO.TB09.01 · 肿瘤生物学

多区域全基因组测序揭示von Hippel-Lindau(VHL)相关透明细胞肾细胞癌的基因组演化和异质性

Genomic evolution and heterogeneity of von Hippel-Lindau (VHL)-associated clear cell renal cell carcinoma revealed by multi-region whole-genome sequencing

海报缩略图:多区域全基因组测序揭示von Hippel-Lindau(VHL)相关透明细胞肾细胞癌的基因组演化和异质性
编号 7507 展板 9 时间 4/22 09:00–12:00 区域 Section 31 主讲 Francesca Corea, MS
分会场 Tumor Heterogeneity
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Francesca Corea1, Husayn A. Pallikonda2, Scott T. C. Shepherd2, Isaline Rowe3, Alessandro Larcher3, Andrea Salonia1, Samra Turajlic2, Thomas J. Mitchell4, Rosa Bernardi5, Umberto Capitanio3

1Università Vita-Salute San Raffaele, Milano, Italy,2The Francis Crick Institute, London, United Kingdom,3Comprehensive Cancer Center/Unit of Urology; URI, IRCCS San Raffaele Hospital, Milano, Italy,4Early Cancer Institute, University of Cambridge, Cambridge, United Kingdom,5Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milano, Italy

摘要 Abstract

中文摘要
体细胞突变的瘤内异质性(ITH)是散发性透明细胞肾细胞癌(ccRCC)的标志。相比之下,遗传性(VHL相关)ccRCC中ITH的程度和性质仍未得到充分表征,这主要归因于此类肿瘤的罕见性。本研究旨在全面表征这种异质性,并阐明其演化动态和生物学相关性。为研究VHL相关ccRCC的瘤内和瘤间异质性,我们对来自两例携带致病性VHL胚系突变患者的6个小(≤3 cm)肾肿瘤的4个空间上不同区域所获取的23份原发肿瘤活检样本进行了多区域全基因组测序(WGS)。分析体细胞单核苷酸变异(SNV)和拷贝数改变(CNA),以重建这些肿瘤的基因组历史。我们发现所有肿瘤均为克隆独立的,各自携带不同的体细胞变异集和染色体拷贝数改变,包括特征性的3p染色体缺失。在单个肿瘤内部,拷贝数图谱在各区域间是同质的,提示这些事件的早期获得。所有肿瘤中均检测到体细胞SNV的亚克隆多样化。值得注意的是,在一例患者中,所分析的三个肿瘤中有两个显示出显著的ITH,大多数突变为单个区域所独有。此外,出现了显著不同的患者特异性分子图谱,其特征为不同的驱动事件和拷贝数景观,且与其临床分级的差异相关。尽管属初步结果,这些发现为VHL相关ccRCC的基因组异质性提供了新见解,推进了我们对遗传性肾癌如何发生和多样化的理解,并有可能为改善VHL疾病患者的临床管理提供依据。
查看英文原文 English abstract
Intra-tumor heterogeneity (ITH) of somatic mutations is a hallmark of sporadic clear cell renal cell carcinoma (ccRCC). In contrast, the extent and nature of ITH in hereditary (VHL-associated) ccRCC remain poorly characterised, primarily due to the rarity of these tumors. This study aims to comprehensively characterise this heterogeneity and elucidate its evolutionary dynamics and biological relevance. To investigate intra- and inter-tumor heterogeneity in VHL-associated ccRCC, we performed multi-region whole-genome sequencing (WGS) of 23 primary tumor biopsies obtained from four spatially distinct regions of six small (≤3 cm) renal tumors across two patients carrying pathogenic germline VHL mutations. Somatic single-nucleotide variants (SNVs) and copy number alterations (CNAs) were analysed to reconstruct the genomic histories of these tumors. We found that all tumors were clonally independent, each harboring distinct sets of somatic variants and chromosomal copy number alterations, including the characteristic chromosome 3p loss. Within individual tumors, copy number profiles were homogeneous across regions, suggesting early acquisition of these events. Subclonal diversification of somatic SNVs was detected in all tumors. Notably, in one patient, two of the three analysed tumors displayed pronounced ITH, with most mutations being unique to a single region. Moreover, markedly distinct patient-specific molecular profiles emerged, characterised by divergent driver events and copy number landscapes that correlated with differences in their clinical grades. Although preliminary, these findings provide new insights into the genomic heterogeneity of VHL-associated ccRCC, advancing our understanding of how inherited kidney cancers develop and diversify, and potentially informing improved clinical management of patients with VHL disease.
利益披露 Disclosure
F. Corea, None.. H. A. Pallikonda, None.. S. T. C. Shepherd, None.. I. Rowe, None. A. Larcher, AB Medica, Telix Pharmaceuticals Travel. Intuitive Surgical, VHL Alliance ). Telix Pharmaceuticals, MSD Other, Consulting or Advisory Role. A. Salonia, Sanofi Other, Consulting or Advisory Role. Astellas Pharma Other, Speakers' Bureau. Konpharma Travel. T. J. Mitchell, None.. R. Bernardi, None. U. Capitanio, MSD Other, Consulting or Advisory Role. Farmitalia Travel.

← 返回 AACR 2026 检索